We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The European Medicines Agency (EMA) is seeking public comment on its transparency rules and protection of personal and commercially confidential data submitted to its clinical trials database. Read More
In a Senate hearing on reauthorization of the 2006 Pandemic and All-Hazards Preparedness Act (PAHPA), FDA Commissioner Robert Califf reiterated the agency’s call for better data and more supply chain notification authority to prevent future drug and medical device shortages. Read More
To reflect the more current organizational structure and processes in its Office of Generic Drugs (OGD), the FDA has published a manual of policies and procedures (MAPPs) update focused on bioequivalence (BE) studies with clinical endpoints. Read More
The number of priority review generics applications awaiting FDA action dropped by 25 percent in the first half of fiscal year 2023, signaling that the agency has improved review efficiency, according to a report published Tuesday. Read More
The FDA has adopted the International Council for Harmonization’s (ICH) revised guideline for quality risk management, releasing it in the form of a final agency guidance that advises pharma companies on risk management methodology, risk-based decision-making and managing subjectivity. Read More
Vanda Pharmaceuticals is suing the FDA, charging that the agency illegally revealed proprietary manufacturing information to companies seeking approval for generic forms of two of Vanda’s patented drugs. Read More
New digital technologies that enable clinical trials to take place in locations other than traditional trial sites are the subject of a long-awaited FDA draft guidance on conducting decentralized trials (DCT). Read More
A group of 26 state attorneys general joined the outcry against Medicare’s ongoing payment restrictions on antiamyloid antibody Alzheimer’s therapeutics, sending a letter to HHS last week calling for full coverage of the drugs. Read More
The FDA outlined its latest thinking on developing nicotine replacement therapy (NRT) drugs in a final guidance released Monday, including detailed recommendations for clinical trials to support product applications. Read More
The FDA’s ability to function is threatened by the loss of public respect for the agency’s science-based decision making, which is “arguably at an all-time low,” said Steven Grossman, executive director of the Alliance for a Stronger FDA. Read More